多克隆抗体对 SARS-CoV2 在小鼠中的药代动力学和药效学影响。
Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice.
机构信息
Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA.
出版信息
Viruses. 2022 Dec 30;15(1):123. doi: 10.3390/v15010123.
Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC and Cl. AUC increased and mean residence time, T, and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure.
尽管目前正在努力通过接种疫苗来预防 SARS-CoV-2 感染，但仍需要治疗工具来应对持续的 COVID-19 大流行。我们在此报告称，COVID-HIGIV 是一种用于治疗 COVID-19 的人免疫球蛋白产品，与对照组相比，它为感染 SARS-CoV-2 的转基因小鼠提供了显著的生存益处。COVID-HIGIV 在静脉给药后，无论健康动物还是 SARS-CoV-2 感染动物，其药代动力学特征在一段时间内均相似，Tmax、Cmax、AUC 和 Cl 相同或可比。与健康动物相比，感染动物的 AUC 增加，平均驻留时间 T 和 Vd 降低。这些数据表明，COVID-HIGIV 在暴露后早期使用可能是治疗 SARS-CoV-2 感染的有效方法。
Zotero 插件